The MISCAN-COLON simulation model for the evaluation of colorectal cancer screening

Computers and Biomedical Research

Volumn 32, Issue 1, 1999, Pages 13-33

  Loeve, F ^a   Boer, R ^a   Van Oortmarssen, G J ^a   Van Ballegooijen, M ^a   Habbema, J D F ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; COLORECTAL CANCER; COMPUTER PROGRAM; DISEASE COURSE; EPIDEMIOLOGICAL DATA; MODEL; PRIORITY JOURNAL; SIMULATION;

EID: 0033034628     PISSN: 00104809     EISSN: None     Source Type: Journal    
DOI: 10.1006/cbmr.1998.1498     Document Type: Article

References (30)

1. Winawer S. J., Fletcher R. H., Miller L., Godlee F., Stolar M. H. Colorectal cancer screening: Clinical guidelines and rationale. Gastroenterology. 112:1997;594-642.
2. Mandel J. S., Bond J. H., Church T. R., Snover D. C., Bradley G. M. Reducing mortality from colorectal cancer by screening for fecal occult blood. N. Engl. J. Med. 328:1993;1365-1371.
3. Hardcastle J. D., Chamberlain J. O., Robinson M. H. E., Moss S. M., Amar S. S. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 348:1996;1472-1477.
4. Kronborg O., Fenger C., Olsen J., Jørgensen O. D., Søndergaard O. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet. 348:1996;1467-1471.
5. Van Oortmarssen G. J., Boer R., Habbema J. D. F., Lubbe J. T. N. Modelling issues in cancer screening. Stat. Methods Med. Res. 4:1995;33-54.
6. Eddy D. M. Screening for colorectal cancer. Ann. Intern. Med. 113:1990;373-384.
7. Wagner J. L., Tunis S., Brown M., Ching A., Almeida R. Cost-effectiveness of colorectal cancer screening in average-risk adults. Prevention and Early Detection of Colorectal Cancer. 1996;Saunders, London. p. 321-356.
8. Geul K. W., Bosman F. T., Van Blankenstein M., Grobbee D. E., Wilson J. H. Prevention of colorectal cancer. Costs and effectiveness of sigmoidoscopy. Scand. J. Gastroenterol. Suppl. 223:1997;79-87.
9. Habbema J. D. F., Van Oortmarssen G. J., Lubbe J. T. N., Van der Maas P. J. The MISCAN simulation program for the evaluation of screening for disease. Comput. Methods Programs Biomed. 20:1984;79-93.
10. Van der Maas P. J., De Koning H. J., Van Ineveld B. M., Van Oortmarssen G. J., Habbema J. D. F. The cost-effectiveness of breast cancer screening. Int. J. Cancer. 43:1989;1055-1060.
11. De Koning H. J., Van Ineveld B. M., Van Oortmarssen G. J., De Haes J. C. J. M., Collette H. J. A. Breast cancer screening and cost-effectiveness: Policy alternatives, quality of life considerations and the possible impact of uncertain factors. Int. J. Cancer. 49:1991;531-537.
12. Van Ballegooijen M., Habbema J. D. F., Van Oortmarssen G. J., Koopmanschap M., Lubbe J. T. N. Preventive pap-smears: Balancing costs, risks and benefitsm. Br. J. Cancer. 65:1992;930-933.
13. Law A. M., Kelton W. D. Simulation Modeling and Analysis. 1982;McGraw-Hill, New York.
14. Mood A. M., Graybill F. A., Boes D. C. Introduction to the Theory of Statistics. 1974;McGraw-Hill.
15. De Vlas S. J., Nagelkerke N. J. D., Habbeman J. D. F., Van Oortmarssen G. J. Statistical models for estimating prevalence and incidence of parasitic diseases. Stat. Methods Med. Res. 2:1993;3-21.
16. Macrae F. A., John D. J. B. S. Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology. 82:1982;891-898.
17. L'Ecuyer P., Côté S. Implementing a random number package with splitting facilities. ACM Trans. Math. Software. 17:1991;98-111.
18. Van Oortmarssen G. J., Habbema J. D. F., Lubbe J. T. N., Van der Maas P. J. A model-based analysis of the HIP project for breast cancer screening. Int. J. Cancer. 46:1990;207-213.
19. Van Oortmarssen G. J., Habbema J. D. F., Van der Maas P. J., De Koning H. J., Collette H. J. A. A model for breast cancer screening. Cancer. 66:1990;1601-1612.
20. De Koning H. J., Boer R., Warmerdam P. G., Beemsterboer P. M., Van der Maas P. J. Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials [see comments]. J. Natl. Cancer Inst. 87:1995;1217-1223.
21. Habbema J. D. F., Van Oortmarssen G. J., Lubbe J. T. N., Van der Maas P. J. Model building on the basis of Dutch cervical cancer screening data. Maturitas. 7:1985;11-20.
22. Van Oortmarssen G. J., Habbema J. D. F., Van Ballegooijen M. Predicting mortality from cervical cancer after negative smear test results. Br. Med. J. 305:1992;449-451.
23. Van Oortmarssen G. J., Habbema J. D. F. The duration of pre-clinical cervical cancer and the reduction in incidence of invasive cancer following negative Pap-smears. Int. J. Epidemiol. 24:1995;300-307.
24. Winawer S. J., Zauber A. G., O'brien M. J., Ho M. N., Gottlieb L. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N. Engl. J. Med. 328:1993;901-906.
25. Van Oortmarssen G. J., Habbema J. D. F. Epidemiological evidence for age-dependent regression of pre-invasive cervical cancer. Br. J. Cancer. 64:1991;559-565.
26. De Koning H. J., Van Oortmarssen G. J., Van Ineveld B. M., Van der Maas P. J. Breast cancer screening: Its impact on clinical medicine. Br. J. Cancer. 61:1990;292-297.
27. De Haes J. C. J. M., De Koning H. J., Van Oortmarssen G. J., Van Agt H. M. E., De Bruyn A. E. The impact of a breast cancer screening programme on quality adjusted life-years. Int. J. Cancer. 49:1991;538-544.
28. Koopmanschap M., Lubbe J. T. N., Van Oortmarssen G. J., Van Agt H. M. E., Van Ballegooijen M. Economic aspects of cervical cancer screening. Social Sci. Med. 30:1990;1081-1087.
29. Koopmanschap M., Van Oortmarssen G. J., Van Agt H. M. A., Van Ballegooijen M., Habbema J. D. F. Cervical-cancer screening: Attendance and cost-effectiveness. Int. J. Cancer. 45:1990;410-415.
30. Van Ballegooijen M., Van den Akker-Van Marle M. E., Warmerdam P. G., Meijer C. J. L. M., Walboomers J. M. M. Present evidence on the value of HPV testing for cervical cancer screening: A model-based exploration of the (cost-)effectiveness. Br. J. Cancer. 76:1997;651-657.